Eli Lilly Space Research

Eli Lilly Space Research represents a unique extension of Eli Lilly and Company’s pharmaceutical research capabilities. Founded in 1876, the company is now conducting research in the realm of space-based medicine, specifically utilizing the microgravity environment of the International Space Station (ISS). Their primary focus is on investigating protein crystal growth and drug formulation in space, seeking to potentially improve the efficacy and development of pharmaceutical products.

While specific mission details are not extensively publicized, this initiative demonstrates a commitment to innovative research methodologies beyond traditional terrestrial laboratories. Eli Lilly leverages its long-standing expertise – over 149 years in developing and delivering trusted medicines – to explore how the unique conditions of space can advance pharmaceutical science.

The company’s broader mission, as evidenced by its overall operations, centers on increasing access to medicines, improving lives and communities, and operating ethically and responsibly. The space research component represents a forward-looking investment in potentially groundbreaking scientific advancements, aligning with their dedication to improving global health. Currently, Lilly supports the health of over 58 million people annually and employs a workforce of 47,000 dedicated to advancing medicine.